These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

105 related items for PubMed ID: 16633147

  • 1. Escitalopram, but not its major metabolites, exhibits antiplatelet activity in humans.
    Atar D, Malinin A, Takserman A, Pokov A, van Zyl L, Tanguay JF, Lesperance F, Serebruany V.
    J Clin Psychopharmacol; 2006 Apr; 26(2):172-7. PubMed ID: 16633147
    [Abstract] [Full Text] [Related]

  • 2. Antiplatelet properties of escitalopram in patients with the metabolic syndrome: a dose-ranging in vitro study.
    Atar D, Malinin A, Pokov A, van Zyl L, Frasure-Smith N, Lesperance F, Serebruany VL.
    Neuropsychopharmacology; 2007 Nov; 32(11):2369-74. PubMed ID: 17356575
    [Abstract] [Full Text] [Related]

  • 3. The in vitro effects of niacin on platelet biomarkers in human volunteers.
    Serebruany V, Malinin A, Aradi D, Kuliczkowski W, Norgard NB, Boden WE.
    Thromb Haemost; 2010 Aug; 104(2):311-7. PubMed ID: 20539903
    [Abstract] [Full Text] [Related]

  • 4. Evaluation of dose-related effects of aspirin on platelet function: results from the Aspirin-Induced Platelet Effect (ASPECT) study.
    Gurbel PA, Bliden KP, DiChiara J, Newcomer J, Weng W, Neerchal NK, Gesheff T, Chaganti SK, Etherington A, Tantry US.
    Circulation; 2007 Jun 26; 115(25):3156-64. PubMed ID: 17562955
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Delayed inhibition of agonist-induced granulocyte-platelet aggregation after low-dose sevoflurane inhalation in humans.
    Wacker J, Lucchinetti E, Jamnicki M, Aguirre J, Härter L, Keel M, Zaugg M.
    Anesth Analg; 2008 Jun 26; 106(6):1749-58. PubMed ID: 18499605
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Valsartan inhibits platelet activity at different doses in mild to moderate hypertensives: Valsartan Inhibits Platelets (VIP) trial.
    Serebruany VL, Pokov AN, Malinin AI, O'Connor C, Bhatt DL, Tanguay JF, Sane DC, Hennekens CH.
    Am Heart J; 2006 Jan 26; 151(1):92-9. PubMed ID: 16368298
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Analysis of platelet alpha2-adrenergic receptor activity in stable coronary artery disease patients on dual antiplatelet therapy.
    Béres BJ, Tóth-Zsámboki E, Vargová K, László A, Masszi T, Kerecsen G, Préda I, Kiss RG.
    Thromb Haemost; 2008 Nov 26; 100(5):829-38. PubMed ID: 18989527
    [Abstract] [Full Text] [Related]

  • 11. Platelet function in clopidogrel-treated patients with acute coronary syndrome.
    Sibbing D, von Beckerath O, Schömig A, Kastrati A, von Beckerath N.
    Blood Coagul Fibrinolysis; 2007 Jun 26; 18(4):335-9. PubMed ID: 17473574
    [Abstract] [Full Text] [Related]

  • 12. Antiplatelet profiles of the fixed-dose combination of extended-release dipyridamole and low-dose aspirin compared with clopidogrel with or without aspirin in patients with type 2 diabetes and a history of transient ischemic attack: a randomized, single-blind, 30-day trial.
    Serebruany VL, Malinin AI, Pokov AN, Hanley DF.
    Clin Ther; 2008 Feb 26; 30(2):249-59. PubMed ID: 18343263
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Glycoprotein Ibalpha inhibition and ADP receptor antagonists, but not aspirin, reduce platelet thrombus formation in flowing blood exposed to atherosclerotic plaques.
    Penz SM, Reininger AJ, Toth O, Deckmyn H, Brandl R, Siess W.
    Thromb Haemost; 2007 Mar 26; 97(3):435-43. PubMed ID: 17334511
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Effects of clopidogrel and aspirin in combination versus aspirin alone on platelet activation and major receptor expression in diabetic patients: the PLavix Use for Treatment Of Diabetes (PLUTO-Diabetes) trial.
    Serebruany VL, Malinin AI, Pokov A, Barsness G, Hanley DF.
    Am Heart J; 2008 Jan 26; 155(1):93.e1-7. PubMed ID: 18082496
    [Abstract] [Full Text] [Related]

  • 18. Hypersensitivity of platelets to adenosine diphosphate in patients with stable cardiovascular disease predicts major adverse events despite antiplatelet therapy.
    Christie DJ, Kottke-Marchant K, Gorman RT.
    Platelets; 2008 Mar 26; 19(2):104-10. PubMed ID: 17852773
    [Abstract] [Full Text] [Related]

  • 19. Lack of association between the 807 C/T polymorphism of glycoprotein Ia gene and post-treatment platelet reactivity after aspirin and clopidogrel in patients with acute coronary syndrome.
    Cuisset T, Frere C, Quilici J, Morange PE, Saut N, Romero-Barra M, Camoin L, Lambert M, Juhan-Vague I, Bonnet JL, Alessi MC.
    Thromb Haemost; 2007 Feb 26; 97(2):212-7. PubMed ID: 17264949
    [Abstract] [Full Text] [Related]

  • 20. Heterozygous loss of platelet glycoprotein (GP) Ib-V-IX variably affects platelet function in velocardiofacial syndrome (VCFS) patients.
    Liang HP, Morel-Kopp MC, Curtin J, Wilson M, Hewson J, Chen W, Ward CM.
    Thromb Haemost; 2007 Dec 26; 98(6):1298-308. PubMed ID: 18064328
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.